Search research articles
Contact Us
Filters
Showing results (81-90 of 96) with videos related to
Page
of 10
Sort By:
Journal of Hepatology
|
September 8, 2020
Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium
Elsa Solà, Elisa Pose, Daniela Campion, et al.
Plos One
|
September 19, 2018
Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care. A population-based study
Núria Fabrellas, Rosario Hernández, Isabel Graupera, et al.
Journal of Hepatology
|
July 17, 2016
Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis
Elsa Solà, Annarein J C Kerbert, Hein W Verspaget, et al.
Journal of Hepatology
|
August 24, 2018
Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial
Elsa Solà, Cristina Solé, Macarena Simón-Talero, et al.
The Lancet. Gastroenterology & Hepatology
|
October 15, 2019
Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial
Elisa Pose, Laura Napoleone, Ahmed Amin, et al.
Hepatology Communications
|
December 29, 2021
Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis
Elisa Pose, Elsa Solà, Juan J Lozano, et al.
Gastroenterologia Y Hepatologia
|
April 11, 2018
Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline
Rocío Aller, Conrado Fernández-Rodríguez, Oreste Lo Iacono, et al.
Gastroenterologia Y Hepatologia
|
June 23, 2018
Erratum to «Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline» [Gastroenterol Hepatol. 2018;41(5):328-349]
Rocío Aller, Conrado Fernández-Rodríguez, Oreste Lo Iacono, et al.
Gut
|
October 26, 2023
Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis
Adrià Juanola, Ann Thu Ma, Koos de Wit, et al.
Journal of Hepatology
|
November 29, 2019
Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF
Richard Moreau, Joan Clària, Ferran Aguilar, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 96) with videos related to
Sort By:
Page
of 10
Journal of Hepatology
|
September 8, 2020
Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium
Elsa Solà, Elisa Pose, Daniela Campion, et al.
Plos One
|
September 19, 2018
Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care. A population-based study
Núria Fabrellas, Rosario Hernández, Isabel Graupera, et al.
Journal of Hepatology
|
July 17, 2016
Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis
Elsa Solà, Annarein J C Kerbert, Hein W Verspaget, et al.
Journal of Hepatology
|
August 24, 2018
Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial
Elsa Solà, Cristina Solé, Macarena Simón-Talero, et al.
The Lancet. Gastroenterology & Hepatology
|
October 15, 2019
Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial
Elisa Pose, Laura Napoleone, Ahmed Amin, et al.
Hepatology Communications
|
December 29, 2021
Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis
Elisa Pose, Elsa Solà, Juan J Lozano, et al.
Gastroenterologia Y Hepatologia
|
April 11, 2018
Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline
Rocío Aller, Conrado Fernández-Rodríguez, Oreste Lo Iacono, et al.
Gastroenterologia Y Hepatologia
|
June 23, 2018
Erratum to «Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline» [Gastroenterol Hepatol. 2018;41(5):328-349]
Rocío Aller, Conrado Fernández-Rodríguez, Oreste Lo Iacono, et al.
Gut
|
October 26, 2023
Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis
Adrià Juanola, Ann Thu Ma, Koos de Wit, et al.
Journal of Hepatology
|
November 29, 2019
Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF
Richard Moreau, Joan Clària, Ferran Aguilar, et al.
Page
of 10